Last reviewed 2026-04-23 · How we verify

GP2015 Etanercept

Sandoz · Phase 3 active Small molecule

GP2015 Etanercept is a TNF-α inhibitor (biosimilar) Small molecule drug developed by Sandoz. It is currently in Phase 3 development for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis. Also known as: GP2015, Etanercept.

GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.

GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.

Likelihood of approval

59.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GP2015 Etanercept
Also known as	GP2015, Etanercept
Sponsor	Sandoz
Drug class	TNF-α inhibitor (biosimilar)
Target	TNF-α (tumor necrosis factor-alpha)
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

Etanercept is a TNF receptor fusion protein that binds and neutralizes TNF-α, a key pro-inflammatory cytokine. By sequestering TNF-α, it prevents interaction with TNF receptors on immune cells and reduces the inflammatory cascade. This mechanism is effective in autoimmune and inflammatory conditions where TNF-α plays a central pathogenic role.

Approved indications

Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Juvenile idiopathic arthritis

Common side effects

Injection site reactions
Upper respiratory tract infections
Headache
Serious infections
Tuberculosis reactivation

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GP2015 Etanercept CI brief — competitive landscape report
GP2015 Etanercept updates RSS · CI watch RSS
Sandoz portfolio CI

Frequently asked questions about GP2015 Etanercept

What is GP2015 Etanercept?

GP2015 Etanercept is a TNF-α inhibitor (biosimilar) drug developed by Sandoz, indicated for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.

How does GP2015 Etanercept work?

GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.

What is GP2015 Etanercept used for?

GP2015 Etanercept is indicated for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Plaque psoriasis, Juvenile idiopathic arthritis.

Who makes GP2015 Etanercept?

GP2015 Etanercept is developed by Sandoz (see full Sandoz pipeline at /company/sandoz).

Is GP2015 Etanercept also known as anything else?

GP2015 Etanercept is also known as GP2015, Etanercept.

What drug class is GP2015 Etanercept in?

GP2015 Etanercept belongs to the TNF-α inhibitor (biosimilar) class. See all TNF-α inhibitor (biosimilar) drugs at /class/tnf-inhibitor-biosimilar.

What development phase is GP2015 Etanercept in?

GP2015 Etanercept is in Phase 3.

What are the side effects of GP2015 Etanercept?

Common side effects of GP2015 Etanercept include Injection site reactions, Upper respiratory tract infections, Headache, Serious infections, Tuberculosis reactivation.

What does GP2015 Etanercept target?

GP2015 Etanercept targets TNF-α (tumor necrosis factor-alpha) and is a TNF-α inhibitor (biosimilar).

Drug class: All TNF-α inhibitor (biosimilar) drugs
Target: All drugs targeting TNF-α (tumor necrosis factor-alpha)
Manufacturer: Sandoz — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Rheumatoid arthritis
Indication: Drugs for Ankylosing spondylitis
Indication: Drugs for Psoriatic arthritis
Also known as: GP2015, Etanercept

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing